Received Dec 22, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEPA | HEP A (HAVRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | — | — |
late 2nd dose; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too long in a 72-year-old male patient who received HAV (Havrix) for prophylaxis. Previously administered products included Havrix (1st dose received on 27-DEC-1995). On 05-JUL-2006, the patient received the 2nd dose of Havrix. On 05-JUL-2006, an unknown time after receiving Havrix, the patient experienced drug dose administration interval too long (Verbatim: late 2nd dose). The outcome of the drug dose administration interval too long was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 15-DEC-2025 As the conversation was transferred to 2nd line agent, HCP asked What happen if a patient has a Havrix and then a hep A vaccine from other manufacture. However, HCP mentioned to 1st line agent that both doses were Havrix. We report this for late 2nd dose and possible interchangeability. The batch number was not provided and we are able to contact the reporter.